---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006690"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:55:39.536979+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports positive Phase 3 results for paridiprubart in ARDS; 28-day mortality reduced 13% absolute

## Summary
- Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.
- Durable survival benefit at 60 days: 46% vs 59% mortality (p=0.003); 13% absolute improvement, 22% relative risk reduction.
- Paridiprubart arm showed 41% higher relative rate of clinical improvement (≥2-point WCSS improvement at Day 28; p=0.032).
- Safety data from >275 subjects: paridiprubart generally well-tolerated, consistent with prior profile.
- Paridiprubart also in U.S. government 'Just Breathe' study; program funded by Government of Canada's Strategic Innovation Fund.

## SEC filing metadata
- accession: 0001171843-25-006690
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325006690/0001171843-25-006690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325006690/f8k_102825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006690
- JSON: https://secwatch.observer/filing/0001171843-25-006690.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.